Please enable JavaScript to continue using this application.

Compare $IMRX vs $LCTX | Chartloom

Compare

$IMRX vs $LCTX

Immuneering Corp · Lineage Cell Therapeutics Inc

IMRX

Immuneering Corp

LCTX

Lineage Cell Therapeutics Inc

Compare $IMRX vs $LCTX

Comparing Immuneering Corp and Lineage Cell Therapeutics Inc

IMRXImmuneering Corp

LCTXLineage Cell Therapeutics Inc

IMRXImmuneering Corp

Market cap

$255M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-40.5%

52W performance

-39.4%

FCF yield

-22.4%

LCTXLineage Cell Therapeutics Inc

Market cap

$248M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

28.49x

Rev growth (TTM)

-37.1%

YTD performance

-39.4%

52W performance

-42.5%

FCF yield

-10.0%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

IMRX

LCTX

Detailed metrics comparison

IMRX

Immuneering Corp

LCTX

Lineage Cell Therapeutics Inc

Market Cap

IMRX$255M

LCTX$248M

Enterprise Value

IMRX$214M

LCTX$210M

Price

IMRX$3.94

LCTX$0.99

P/E Ratio

IMRXN/A

LCTXN/A

P/S Ratio

IMRX526.64x

LCTX18.94x

EV/Sales

IMRX443.99x

LCTX16.09x

EV/EBITDA

IMRX0.00x

LCTX0.00x

P/B Ratio

IMRX1.38x

LCTX3.86x

P/FCF Ratio

IMRXN/A

LCTXN/A

EV/FCF

IMRX-3.75x

LCTX-8.48x

PEG Ratio

IMRXN/A

LCTXN/A

Forward P/E (NTM)

IMRXN/A

LCTXN/A

Forward P/S (NTM)

IMRXN/A

LCTX28.49x

Revenue (TTM)

IMRX$0

LCTX$13M

Revenue Growth (YoY)

IMRXN/A

LCTX-37.1%

Forward Rev Growth

IMRX100.5%

LCTX-16.6%

Gross Margin (TTM)

IMRX28.0%

LCTX94.1%

Operating Margin (TTM)

IMRX0.0%

LCTX0.0%

EBITDA Margin (TTM)

IMRX0.0%

LCTX-199.6%

Net Margin (TTM)

IMRX0.0%

LCTX-246.6%

FCF Margin (TTM)

IMRXN/A

LCTX-189.7%

Net Income (TTM)

IMRX$-57M

LCTX$-32M

FCF (TTM)

IMRX$-57M

LCTX$-25M

EPS (TTM)

IMRX-$0.89

LCTX-$0.13

ROE (TTM)

IMRX-2715.0%

LCTX-7114.0%

ROA (TTM)

IMRX-2574.0%

LCTX-3087.0%

ROIC (TTM)

IMRX-2715.0%

LCTX-7104.0%

Cash

IMRX$41M

LCTX$37M

Debt

IMRX$0

LCTX$48K

Net Cash/Debt

IMRX$41M

LCTX$37M

Current Ratio (TTM)

IMRX19.47x

LCTX6.61x

Quick Ratio (TTM)

IMRX18.47x

LCTX6.44x

Debt/Equity (TTM)

IMRX0.00x

LCTX0.00x

Debt/Assets (TTM)

IMRX0.0%

LCTX0.0%

Interest Coverage (TTM)

IMRXN/A

LCTXN/A

Net Debt/EBITDA (TTM)

IMRX0.00x

LCTX0.00x

Beta

IMRX0.34

LCTX1.67

52W Performance

IMRX-39.4%

LCTX-42.5%

YTD Performance

IMRX-40.5%

LCTX-39.4%

% from 52W High

IMRX-53.5%

LCTX-52.4%

% from 52W Low

IMRX9.4%

LCTX12.7%

Asset Turnover (TTM)

IMRX0.00x

LCTX0.07x

FCF Yield (TTM)

IMRX-22.4%

LCTX-10.0%

Earnings Yield (TTM)

IMRX-22.5%

LCTX-13.0%

Dividend Yield (TTM)

IMRXN/A

LCTXN/A

Rule of 40

IMRX0.0

LCTX-226.8

EV/GP/RG

IMRXN/A

LCTXN/A

Ticker research

View IMRX research View LCTX research

Metric	IMRX Immuneering Corp	LCTX Lineage Cell Therapeutics Inc
Market & Valuation
Market Cap	$255M	$248M
Enterprise Value	$214M	$210M
Price	$3.94	$0.99
P/E Ratio	N/A	N/A
P/S Ratio	526.64x	18.94x
EV/Sales	443.99x	16.09x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.38x	3.86x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.75x	-8.48x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	28.49x
Revenue & Growth
Revenue (TTM)	$0	$13M
Revenue Growth (YoY)	N/A	-37.1%
Forward Rev Growth	100.5%	-16.6%
Profitability
Gross Margin (TTM)	28.0%	94.1%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-199.6%
Net Margin (TTM)	0.0%	-246.6%
FCF Margin (TTM)	N/A	-189.7%
Net Income (TTM)	$-57M	$-32M
FCF (TTM)	$-57M	$-25M
EPS (TTM)	-$0.89	-$0.13
ROE (TTM)	-2715.0%	-7114.0%
ROA (TTM)	-2574.0%	-3087.0%
ROIC (TTM)	-2715.0%	-7104.0%
Financial Health
Cash	$41M	$37M
Debt	$0	$48K
Net Cash/Debt	$41M	$37M
Current Ratio (TTM)	19.47x	6.61x
Quick Ratio (TTM)	18.47x	6.44x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.34	1.67
52W Performance	-39.4%	-42.5%
YTD Performance	-40.5%	-39.4%
% from 52W High	-53.5%	-52.4%
% from 52W Low	9.4%	12.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.07x
FCF Yield (TTM)	-22.4%	-10.0%
Earnings Yield (TTM)	-22.5%	-13.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-226.8
EV/GP/RG	N/A	N/A
Ticker research	View IMRX research	View LCTX research

Valuation

P/S Ratio

LCTX

18.94x

IMRX

526.64x

EV/FCF

LCTX

-8.48x

IMRX

-3.75x

Growth & revenue

Revenue Growth TTM

LCTX

-37.1%

Forward Revenue Growth

IMRX

100.5%

LCTX

-16.6%

Profitability & performance

Gross Margin

LCTX

94.1%

IMRX

28.0%

ROE

IMRX

-2715.0%

LCTX

-7114.0%

FCF Yield %

LCTX

-10.0%

IMRX

-22.4%

52-Week Performance

IMRX

-39.4%

LCTX

-42.5%

Detailed metrics comparison

IMRX

Immuneering Corp

LCTX

Lineage Cell Therapeutics Inc

Market Cap

IMRX$255M

LCTX$248M

Enterprise Value

IMRX$214M

LCTX$210M

Price

IMRX$3.94

LCTX$0.99

P/E Ratio

IMRXN/A

LCTXN/A

P/S Ratio

IMRX526.64x

LCTX18.94x

EV/Sales

IMRX443.99x

LCTX16.09x

EV/EBITDA

IMRX0.00x

LCTX0.00x

P/B Ratio

IMRX1.38x

LCTX3.86x

P/FCF Ratio

IMRXN/A

LCTXN/A

EV/FCF

IMRX-3.75x

LCTX-8.48x

PEG Ratio

IMRXN/A

LCTXN/A

Forward P/E (NTM)

IMRXN/A

LCTXN/A

Forward P/S (NTM)

IMRXN/A

LCTX28.49x

Revenue (TTM)

IMRX$0

LCTX$13M

Revenue Growth (YoY)

IMRXN/A

LCTX-37.1%

Forward Rev Growth

IMRX100.5%

LCTX-16.6%

Gross Margin (TTM)

IMRX28.0%

LCTX94.1%

Operating Margin (TTM)

IMRX0.0%

LCTX0.0%

EBITDA Margin (TTM)

IMRX0.0%

LCTX-199.6%

Net Margin (TTM)

IMRX0.0%

LCTX-246.6%

FCF Margin (TTM)

IMRXN/A

LCTX-189.7%

Net Income (TTM)

IMRX$-57M

LCTX$-32M

FCF (TTM)

IMRX$-57M

LCTX$-25M

EPS (TTM)

IMRX-$0.89

LCTX-$0.13

ROE (TTM)

IMRX-2715.0%

LCTX-7114.0%

ROA (TTM)

IMRX-2574.0%

LCTX-3087.0%

ROIC (TTM)

IMRX-2715.0%

LCTX-7104.0%

Cash

IMRX$41M

LCTX$37M

Debt

IMRX$0

LCTX$48K

Net Cash/Debt

IMRX$41M

LCTX$37M

Current Ratio (TTM)

IMRX19.47x

LCTX6.61x

Quick Ratio (TTM)

IMRX18.47x

LCTX6.44x

Debt/Equity (TTM)

IMRX0.00x

LCTX0.00x

Debt/Assets (TTM)

IMRX0.0%

LCTX0.0%

Interest Coverage (TTM)

IMRXN/A

LCTXN/A

Net Debt/EBITDA (TTM)

IMRX0.00x

LCTX0.00x

Beta

IMRX0.34

LCTX1.67

52W Performance

IMRX-39.4%

LCTX-42.5%

YTD Performance

IMRX-40.5%

LCTX-39.4%

% from 52W High

IMRX-53.5%

LCTX-52.4%

% from 52W Low

IMRX9.4%

LCTX12.7%

Asset Turnover (TTM)

IMRX0.00x

LCTX0.07x

FCF Yield (TTM)

IMRX-22.4%

LCTX-10.0%

Earnings Yield (TTM)

IMRX-22.5%

LCTX-13.0%

Dividend Yield (TTM)

IMRXN/A

LCTXN/A

Rule of 40

IMRX0.0

LCTX-226.8

EV/GP/RG

IMRXN/A

LCTXN/A

Ticker research

View IMRX research View LCTX research

Metric	IMRX Immuneering Corp	LCTX Lineage Cell Therapeutics Inc
Market & Valuation
Market Cap	$255M	$248M
Enterprise Value	$214M	$210M
Price	$3.94	$0.99
P/E Ratio	N/A	N/A
P/S Ratio	526.64x	18.94x
EV/Sales	443.99x	16.09x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.38x	3.86x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.75x	-8.48x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	28.49x
Revenue & Growth
Revenue (TTM)	$0	$13M
Revenue Growth (YoY)	N/A	-37.1%
Forward Rev Growth	100.5%	-16.6%
Profitability
Gross Margin (TTM)	28.0%	94.1%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-199.6%
Net Margin (TTM)	0.0%	-246.6%
FCF Margin (TTM)	N/A	-189.7%
Net Income (TTM)	$-57M	$-32M
FCF (TTM)	$-57M	$-25M
EPS (TTM)	-$0.89	-$0.13
ROE (TTM)	-2715.0%	-7114.0%
ROA (TTM)	-2574.0%	-3087.0%
ROIC (TTM)	-2715.0%	-7104.0%
Financial Health
Cash	$41M	$37M
Debt	$0	$48K
Net Cash/Debt	$41M	$37M
Current Ratio (TTM)	19.47x	6.61x
Quick Ratio (TTM)	18.47x	6.44x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.34	1.67
52W Performance	-39.4%	-42.5%
YTD Performance	-40.5%	-39.4%
% from 52W High	-53.5%	-52.4%
% from 52W Low	9.4%	12.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.07x
FCF Yield (TTM)	-22.4%	-10.0%
Earnings Yield (TTM)	-22.5%	-13.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-226.8
EV/GP/RG	N/A	N/A
Ticker research	View IMRX research	View LCTX research